PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.58%
Negative EBIT growth while AVXL is at 52.20%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-14.34%
Negative operating income growth while AVXL is at 52.20%. Joel Greenblatt would press for urgent turnaround measures.
-20.40%
Negative net income growth while AVXL stands at 51.67%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-19.61%
Negative EPS growth while AVXL is at 51.76%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-20.61%
Negative diluted EPS growth while AVXL is at 51.76%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.76%
Share change of 0.76% while AVXL is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.74%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-26.42%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-91846.40%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-21838.35%
Negative 5Y OCF/share CAGR while AVXL is at 49.54%. Joel Greenblatt would question the firm’s operational model or cost structure.
2.60%
Positive 3Y OCF/share CAGR while AVXL is negative. John Neff might see a big short-term edge in operational efficiency.
-1109485.80%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-20425.82%
Negative 5Y net income/share CAGR while AVXL is 74.81%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
78.21%
Positive short-term CAGR while AVXL is negative. John Neff would see a clear advantage in near-term profit trajectory.
41985.76%
10Y equity/share CAGR above 1.5x AVXL's 8723.17%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
3459.24%
5Y equity/share CAGR above 1.5x AVXL's 234.58%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
143.15%
Below 50% of AVXL's 380.27%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.02%
Negative asset growth while AVXL invests at 125.02%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-29.04%
We have a declining book value while AVXL shows 204.04%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
15.43%
We increase R&D while AVXL cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
12.93%
We expand SG&A while AVXL cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.